Navigation Links
Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
Date:4/15/2008

JAMESBURG, N.J., April 15 /PRNewswire/ -- Phytomedics Inc., an innovative clinical stage biopharmaceutical company pioneering the development novel multi-mechanism therapeutics from natural sources, today announced that Dr. Laurie Smaldone Alsup, MD., has joined the company as its President and Chief Executive Officer. She succeeds Dr. Bertold Fridlender who is announcing his retirement, but who will remain on the company's board of directors.

"Dr. Smaldone Alsup brings to Phytomedics an extensive background in drug development as well as executive leadership in various roles," said Aki von Roy, chairman of Phytomedics board of directors. "Her distinguished career and accomplishments in the pharmaceutical industry will be an invaluable asset in moving Phytomedics products forward into the market place."

Prior to joining Phytomedics, Dr. Smaldone Alsup served a distinguished 16-year career at Bristol-Myers Squibb in various executive and R&D roles. Most recently she was VP of Corporate Strategy and Issues Management involved in developing a corporate-wide business risk management capability and process. Previously, Dr. Smaldone Alsup headed Global Regulatory Sciences for the Pharmaceutical Research Institute, overseeing the regulatory approval process and pharmacovigilance for all products. She initially joined the company as a director of clinical research oncology and held clinical development positions of increasing responsibility including oversight for HIV/AIDS and infectious diseases. In these positions, Dr. Smaldone Alsup has played a role in the development of new medications to treat chronic, debilitating, and fatal diseases. She holds an M.D. degree from Yale University School of Medicine, New Haven, CT.

Dr. Smaldone Alsup has conducted clinical research throughout her career, which has been published in medical journals and presented to her peers at leading medical symposia and congresses. Dr. Smaldone Alsup serves on the board of the Hi-Tops Teen Reproductive Health Organization and McCarter Theater in Princeton, NJ. She is also a member of The Conference Board's Strategic Risk Management Council as well as a member of the Council's Executive Committee.

"The position of President and Chief Executive Officer of Phytomedics is an outstanding opportunity to lead a company with a promising future," said Smaldone Alsup. "I look forward to advancing our strong pipeline of products through the clinic and into the market to deliver innovative and efficacious products to patients."

Commenting of Dr. Fridlender's retirement, "Dr. Fridlender has done a terrific job in transitioning Phytomedics from a virtual company, to one with a broad product pipeline, multiple technologies, and a potential blockbuster product already in late stage development," said von Roy. "We now look forward to a new era in our company's development as we transition towards our commercialization strategy."

About Phytomedics, Inc.

Phytomedics Inc. (http://www.phytomedics.com) is focused on the discovery, development, manufacture, and commercialization novel, multi-component and multi-functional drugs from natural sources. The Company has produced a pipeline of lead compounds, several of which are in clinical development, some as far as Phase IIb. Founded by Professor Ilya Raskin, Ph.D., Phytomedics Inc. conducts most of its R&D at the Biotech Center of Rutgers University.


'/>"/>
SOURCE Phytomedics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Phytomedics Inc. to Present at Wachovia 2008 Healthcare Conference
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... Staten Island, NY (PRWEB) , ... January 19, 2017 , ... ... expand at an exponential rate. The tremendous growth is accounted to two main ... to the table and the expanding network of vendors supplying FireflySci products all around ...
(Date:1/19/2017)... FRANKLIN LAKES, N.J. , Jan. 18, 2017 BD ... medical technology company, announced today that it will host a live ... 2017, at 1 p.m. (ET). The webcast can ... will be available for replay through Tuesday, January 31, 2017. ... About BD ...
(Date:1/18/2017)... N.J. , Jan. 18, 2017   Parent ... the fight to end Duchenne muscular dystrophy (Duchenne) ... to the New Jersey Institute of Technology (NJIT) and ... exploration of robotic technology to assist people ... to incorporate NJIT,s technology – an embedded computer, software, ...
Breaking Biology Technology:
(Date:12/8/2016)... Market Research Future published a half cooked research report ... Security and Service Market is expected to grow over the CAGR ... Highlights: ... Mobile Biometric Security and Service Market is ... of authentication and security from unwanted cyber threats. The increasing use ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
Breaking Biology News(10 mins):